CPG
ANIK icon

Cornerstone Planning Group’s Anika Therapeutics ANIK Stock Holding History

Cornerstone Planning Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27
Closed -$225 – 1699
2025
Q2 		$225 Buy
+27
New +$341 ﹤0.01% 1453
2025
Q1 		– Sell
-20
Closed -$334 – 1563
2024
Q4 		$334 Buy
+20
New +$394 ﹤0.01% 1264

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cornerstone Planning Group's ANIK Position: Q3 2025 in Review

Cornerstone Planning Group sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 27 shares — an estimated $225 sold.

Cornerstone Planning Group first reported a position in ANIK in Q4 2024 and held it in 2 quarters. The position peaked at $334 in Q4 2024. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Cornerstone Planning Group reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 27 Anika Therapeutics shares in Q3 2025, an estimated $225.
  • Cornerstone Planning Group first reported a position in Anika Therapeutics in Q4 2024 and held it in 2 quarters.
  • Cornerstone Planning Group's Anika Therapeutics position peaked at $334 in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Cornerstone Planning Group's 13F filing for Q3 2025, filed 4 Nov 2025.